Proliferative glomerulonephritis with monoclonal immunoglobulin deposits: a nephrologist perspective
- 5 September 2019
- journal article
- review article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 36 (2), 208-215
- https://doi.org/10.1093/ndt/gfz176
Abstract
Proliferative glomerulonephritis (GN) with monoclonal immunoglobulin deposits (PGNMIDs) is a recently described entity among the spectrum of monoclonal gammopathy of renal significance (MGRS). The disease is renal limited and manifests with chronic glomerular disease, altered renal function and albuminuria, sometimes in the nephrotic range. Acute nephritic syndrome is rare. PGNMID occurs mostly in the sixth decade, but it may affect young adults. Histologically, PGNMID is characterized predominantly by membranoproliferative GN and less frequently by diffuse endocapillary GN, mesangioproliferative GN or atypical membranous GN. Immunofluorescence and electron microscopic studies are the cornerstone of diagnosis, showing granular deposits involving glomeruli only, and composed of monotypic immunoglobulin G (IgG), with a single heavy chain subclass (most commonly IgG3) and light chain (LC) restriction (usually κ), admixed with complement deposits. PGNMID variants with monotypic LC-only, IgA or IgM deposits are uncommon. Ultrastructurally, deposits are amorphous with predominant subendothelial and mesangial distribution. PGNMID should be distinguished from type 1 cryoglobulinemic GN and immunotactoid GN, which share some common pathological features. Contrary to other MGRS lesions, the rate of detection of the nephrotoxic monoclonal Ig in the serum or urine, and of an abnormal bone marrow B-cell clone, is only ∼30%. Renal prognosis is poor, with progression to end-stage renal disease in 25% of patients within 30 months and frequent early recurrence on the renal allograft. The pathophysiology of PGNMID is unclear and its treatment remains challenging. However, recent studies indicate that clone-targeted chemotherapy may significantly improve renal outcomes, opening future perspectives for the management of this rare disease.Keywords
This publication has 47 references indexed in Scilit:
- The pathogenesis and diagnosis of acute kidney injury in multiple myelomaNature Reviews Nephrology, 2011
- Proliferative Glomerulonephritis With Monoclonal IgG Deposits Recurs or May Develop De Novo in Kidney AllograftsAmerican Journal of Kidney Diseases, 2011
- Patterns of Noncryoglobulinemic Glomerulonephritis with Monoclonal Ig DepositsClinical Journal of the American Society of Nephrology, 2011
- Proliferative glomerulonephritis with monoclonal IgG deposits secondary to chronic lymphocytic leukemia. Report of two casesNephrology Dialysis Transplantation, 2011
- Proliferative Glomerulonephritis with Monoclonal IgG Deposits Recurs in the AllograftClinical Journal of the American Society of Nephrology, 2011
- Proliferative Glomerulonephritis with Monoclonal IgG DepositsJournal of the American Society of Nephrology, 2009
- Expanding the pathologic spectrum of light chain deposition disease: a rare variant with clinical follow-up of 7 yearsLaboratory Investigation, 2005
- Reversal of dialysis-dependent renal failure in light-chain deposition disease by autologous peripheral blood stem cell transplantationAmerican Journal of Kidney Diseases, 2004
- Reversal of dialysis-dependent renal failure in light-chain deposition disease by autologous peripheral blood stem cell transplantationAmerican Journal of Kidney Diseases, 2004
- Proliferative glomerulonephritis with monoclonal IgG deposits: A distinct entity mimicking immune-complex glomerulonephritisKidney International, 2004